AC Immune (ACIU) Accumulated Expenses (2015 - 2026)
AC Immune (ACIU) posted quarterly Accumulated Expenses of $8.3 billion for Q1 2026, up 66535.86% year-over-year from N/an in Q1 2025, and down 18.15% quarter-over-quarter from $10.1 billion in Q4 2025.
AC Immune (ACIU) Accumulated Expenses (2015 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Accumulated Expenses for 12 consecutive years, with $8.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 66535.86% year-over-year to $8.3 billion; the TTM figure through Mar 2026 stood at $8.3 billion (up 66535.86% YoY), while the FY2025 annual figure was $9.7 billion, up 70354.35% from the prior year.
- Accumulated Expenses eased to $8.3 billion in Q1 2026 per ACIU's latest filing, from $10.1 billion in the prior quarter.
- Across five years, Accumulated Expenses topped out at $12.5 billion in Q4 2023 and bottomed at $9.4 million in Q1 2023.
- Historically, Accumulated Expenses has averaged $2.5 billion across 5 years, with a median of $13.2 million in 2024.
- Annual changes were most pronounced in 2022 — Accumulated Expenses tumbled 99.95% — and 2023, when it jumped 127766.11%.
- AC Immune's Accumulated Expenses stood at $9.8 million in 2022, then surged by 127766.11% to $12.5 billion in 2023, then sank by 99.89% to $13.8 million in 2024, then jumped by 72985.38% to $10.1 billion in 2025, then decreased by 18.15% to $8.3 billion in 2026.
- Business Quant data shows ACIU's Accumulated Expenses at $8.3 billion in Q1 2026, $10.1 billion in Q4 2025, and $15.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.01 Mn |
| Mar 31, 2026 | 8.26 Bn |
| Dec 31, 2025 | 10.09 Bn |
| Sep 30, 2025 | 14.99 Mn |
| Jun 30, 2025 | 13.86 Mn |
| Mar 31, 2025 | 12.40 Mn |
| Dec 31, 2024 | 13.81 Mn |
| Sep 30, 2024 | 14.89 Mn |
| Jun 30, 2024 | 13.15 Mn |
| Mar 31, 2024 | 12.08 Mn |
| Dec 31, 2023 | 12.50 Bn |
| Sep 30, 2023 | 10.57 Mn |
| Jun 30, 2023 | 12.35 Mn |
| Mar 31, 2023 | 9.36 Mn |
| Dec 31, 2022 | 9.78 Mn |
| Sep 30, 2022 | 11.37 Mn |
| Jun 30, 2022 | 9.76 Mn |
| Mar 31, 2022 | 11.45 Bn |
| Dec 31, 2021 | 18.15 Bn |
| Sep 30, 2021 | 14.49 Bn |